Edwards Lifesciences Corporation
EW | NYSE
$92.01
-$2.43 (-2.57%)
At close: Oct 30, 2026, 4:00 PM ET
$92.61
+$0.60 (+0.65%)
Pre-market:
Nov 2, 2026, 7:00 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 6.07B | 5.44B | 5.01B | 5.38B | 5.23B | 4.39B |
Cost of Revenue | 1.33B | 1.12B | 1.04B | 1.17B | 1.23B | 1.1B |
Gross Profit | 4.74B | 4.32B | 3.97B | 4.22B | 4.01B | 3.29B |
Operating Income | 1.64B | 1.38B | 1.43B | 1.7B | 1.61B | 1.3B |
Interest Income | 148.4M | 120.3M | 67.2M | 35.5M | 17.4M | 23.4M |
Pretax Income | 1.27B | 1.55B | 1.37B | 1.77B | 1.7B | 916.7M |
Net Income | 1.07B | 4.17B | 1.4B | 1.52B | 1.5B | 823.4M |
Selling & General & Admin | 2.09B | 1.79B | 1.58B | 1.57B | 1.49B | 1.23B |
Research & Development | 1.08B | 1.05B | 962.9M | 945.2M | 903.1M | 760.7M |
Other Expenses | -59.9M | 101.1M | n/a | n/a | n/a | n/a |
Operating Expenses | 3.1B | 2.94B | 2.55B | 2.51B | 2.4B | 1.99B |
Interest Expense | n/a | 19.8M | 17.6M | 26.2M | 24.8M | 22.2M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.43B | 4.06B | 3.58B | 3.68B | 3.62B | 3.09B |
Income Tax Expense | 216.9M | 152.1M | 152.4M | 245.5M | 198.9M | 93.3M |
Shares Outstanding (Basic) | 584.8M | 597.7M | 606.7M | 619M | 623.3M | 622.6M |
Shares Outstanding (Diluted) | 585.8M | 599.3M | 609.4M | 624.2M | 631.2M | 631.9M |
EPS (Basic) | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 | 1.32 |
EPS (Diluted) | 1.83 | 6.97 | 2.30 | 2.44 | 2.38 | 1.30 |
EBITDA | 1.43B | 1.72B | 1.53B | 1.96B | 1.89B | 1.07B |
EBIT | 1.27B | 1.57B | 1.39B | 1.79B | 1.73B | 938.9M |
Depreciation & Amortization | 156.6M | 155.2M | 144.9M | 166.8M | 163.3M | 135.4M |
Add to Watchlist
Select watchlists to add or remove EW